VRT-325

• Description:

  VRT-325 is a novel small molecule discovered by screening a compound library designed to address the genetic defect in cystic fibrosis (CF) caused by the ΔF508 mutation in CFTR. VRT-325 belongs to a class of compounds that promote ΔF508-CFTR efflux from the endoplasmic reticulum and restores chloride transport levels in epithelial cells of CF-derived bronchi[1].

• Product Name Alternative:

  4-Hydroxy-TEMPO-d17,15N

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  CFTR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/vrt-325.html

• Purity:

  99.15

• Smiles:

  CC(N1CCN(CC1)S(=O)(C2=CC=C(C=C2)OC)=O)C3=NC(OC4CCCCC4)=C5C=CC=CC5=N3

• Molecular Formula:

  C27H34N4O4S

• Molecular Weight:

  510.65

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Van Goor F, et al. Rescue of ﾎ508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules[J]. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2006, 290 (6) : L1117-L1130.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [815592-21-3]